Theresa Marie Heggie
Independent Non-Executive DirectorMs. Theresa Marie Heggie serves as Member of Scientific Advisory Board at Invivo Partners S.G.E.I.C. S.A. She is Biopharmaceutical Executive & Board Member. She is a highly accomplished executive in the biotech and pharmaceutical industries, with extensive leadership experience spanning global commercial strategy and operations, business development and market access. She serves as Independent Non-Executive Director at ProQR Therapeutics N. V. since May 2024 and served as its Supervisory Board Member since May 18, 2023. She served as Chief Operating Officer at ProQR Therapeutics N. V. from February 2022 to October 2022 served as its Chief Commercial Officer since October 2021 until 2022 and served as Supervisory Board Member since July 1, 2019, until October 2021. She had been the Chief Executive Officer and Director of Freeline Therapeutics Limited since June 1, 2020, until August 16, 2021. Ms. Heggie served as the Chief Executive Officer from June 2020 to August 2021 and Director at Freeline Therapeutics Holdings plc since June 1, 2020. Ms. Heggie is an accomplished rare disease leader and has a broad experience in rare diseases, a deep understanding of medicines for genetic diseases and direct experience. She has experience in the commercial biotech sector. She served as the Head of Europe & Canada (CEMEA) and Senior Vice President at Alnylam Pharmaceuticals, Inc. since May 09, 2017, until May 2020. Prior to June 2013, Ms. Heggie served in senior commercial and operating roles at Shire plc, including Senior Vice President, Global Commercial Operations for the rare disease business. Prior to that, Ms. Heggie had responsibility over EMEA rare disease and served as Chief Executive Officer of Jerini AG. Prior to joining Shire, Ms. Heggie spent in a broad range of increasingly senior commercial positions at Janssen Pharmaceuticals and Baxter Healthcare. Ms. Heggie served as the Chief Marketing and Strategy Officer at The British United Provident Association Limited from June 2013 to December 2015. From June 2013 to March 2016, Ms. Heggie served as Chief Strategy and Marketing Officer for Bupa, an international healthcare group. She served as the Chief Executive Officer of Jerini AG. She served as Vice President and General Manager of Europe of Shire Human Genetic Therapies, Inc. (Shire HGT). She served as Vice President of Shire plc. She served as the European General Manager of Transkaryotic Therapies Inc. (TKT Europe) since March 2005. She served as the Chief Executive Officer and Member of Management Board of Shire Orphan Therapies GmbH since October 2008. She served as Vice President of Global Marketing for the Anesthesia and Critical Care Business of Baxter Healthcare. Early in her career, she held Sales Representative positions at Dow Chemical and Janssen Pharmaceuticals before assuming a variety of marketing positions at Ohmeda Pharmaceutical Products Division (PPD) from 1991 to 1998. She serves as a Director of HealthXL Limited. She serves as Independent Director of BioCryst Pharmaceuticals since December 3, 2018. She served as a Director of Swedish Orphan Biovitrum AB from May 24, 2016, to April 7, 2017. She received a BSc from Cornell University.
Positions
- Company NameProQR Therapeutics N.V.Stock CodePRQRPositionIndependent Non-Executive DirectorColleagues
- DADaniel Anton de BoerFounder, CEO & Executive Director
- JSJames S. ShannonIndependent Chairman of the Board & Chairman of Scientific Advisory Board
- GPGerard PlatenburgCo-Founder, Chief Scientific Officer & Executive Director
- DHDennis HomChief Financial Officer
- SSSheila SponseleeChief People & Operations Officer
- SCSarah Cue KielyVice President of Investor Relations & Corporate Communications
- BFBart FiliusIndependent Non-Executive Director
